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AbstrAct
Introduction Abiraterone acetate plus prednisone (AAP) 
and enzalutamide (ENZ) are commonly prescribed for 
metastatic castration-resistant prostate cancer (mCRPC). 
Data comparing their effects on patient-reported outcomes 
(PROs) from routine clinical practice are limited.
Methods AQUARiUS (NCT02813408) is an ongoing, 
two-cohort, prospective, observational, non-randomised, 
multicentre, phase IV European study assessing the effects 
of AAP and ENZ on PROs in 211 patients with mCRPC over 
12 months. Patients receive AAP or ENZ per routine clinical 
practice. Data on cognition, fatigue, pain and health-
related quality of life are measured using the Functional 
Assessment of Cancer Therapy-Cognitive Function, Brief 
Fatigue Inventory-Short Form, Brief Pain Inventory-Short 
Form and European Organization for Research and 
Treatment of Cancer Quality of Life-C30 questionnaires, 
respectively.
Results This 3-month analysis was conducted in 105 
patients; 46 received AAP and 59 received ENZ. There 
were statistically significant differences in mean change 
from baseline favouring AAP over ENZ at months 1, 2 
and 3 for perceived cognitive impairments and cognitive 
functioning. At each time-point, ENZ-treated patients 
had a significantly higher risk of experiencing clinically 
meaningful worsening in perceived cognitive impairments 
versus those receiving AAP. Statistically significant 
differences in mean change from baseline favouring AAP 
over ENZ were seen for usual level of fatigue and fatigue 
interference at months 2 and 3 and for current fatigue and 
worse level of fatigue at month 3. Differences favouring 
AAP versus ENZ were seen for the fatigue scale of the 
QLQ-C30 questionnaire (months 1 and 3). There was a 
significantly higher risk of clinically meaningful worsening 
in usual level of fatigue with ENZ versus AAP at month 
3. No significant differences between cohorts were 
observed for pain (BPI-SF) at any time-point.
Conclusion This analysis suggests more favourable 
outcomes with AAP versus ENZ for cognition and fatigue in 
the first 3 months of treatment initiation for mCRPC. These 
findings require confirmation from future analyses of data 
from AQUARiUS from a larger number of patients with a 
longer follow-up period.
IntRoduCtIon
Although approximately 90% of patients 
with metastatic prostate cancer respond to 
androgen deprivation therapy (ADT),1 after 
Key questions
What is already known about this subject?
 ► Abiraterone acetate plus prednisone (AAP) and en-
zalutamide (ENZ) have been shown to independently 
delay radiographic progression and extend surviv-
al in patients with metastatic castration-resistant 
prostate cancer (mCRPC).
 ► Although limited, clinical data suggest that cognitive 
and pain outcomes were more favourable in patients 
treated with AAP versus prednisone and with ENZ 
versus placebo.
What does this study add?
 ► This 3-month analysis of AQUARiUS showed signif-
icant differences favouring AAP over ENZ in cogni-
tive outcome measures within the first 3 months 
of treatment initiation and in fatigue from month 2 
onwards.
 ► No significant differences for pain scales were seen 
during the first 3 months of treatment.
How might this impact on clinical practice?
 ► AAP and ENZ have both demonstrated improved 
survival in the treatment of mCRPC.
 ► Differences in patient-reported outcomes may 
aid physicians to determine the most appropriate 
course of treatment in specific patients.
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2–3 years of remission, virtually all metastatic disease will 
ultimately progress to castration-resistant prostate cancer 
(CRPC). Furthermore, of patients diagnosed with CRPC 
with no metastases, 33% are likely to develop metastases 
within 2 years1. Metastatic CRPC (mCRPC) is associated 
with an expected survival of between 15 and 36 months 
according to recent studies.2 In addition to a poor prog-
nosis, patients with mCRPC are likely to experience 
deterioration in health-related quality of life (HRQoL) 
and progressive worsening of pain.3 Docetaxel was the 
standard of care for mCRPC; however, since 2010, a 
number of other treatment options have become avail-
able, including abiraterone acetate plus prednisone 
(AAP) and enzalutamide (ENZ), both androgen-targeted 
therapies that have been shown to delay radiographic 
progression and increase survival compared with pred-
nisone or placebo, respectively, in clinical trials.4–8 Being 
non-cytotoxic, life-extending therapies, AAP and ENZ 
have the potential to affect HRQoL and pain positively as 
compared with chemotherapy, as well as other patient-re-
ported outcomes (PROs), such as fatigue and cognitive 
function, striking a more favourable balance between 
cancer control and toxicity than cytotoxic alternatives.3 
Indeed, data from phase III trials of AAP and ENZ (COU-
AA-302 and PREVAIL, respectively) showed that chemo-
therapy-naïve patients with mCRPC treated with either 
agent experienced delayed deterioration in HRQoL, 
defined as a decrease of at least 10 points in global score 
on the Functional Assessment of Cancer Therapy-Prostate 
(FACT-P) scale, compared with controls (12.7 months vs 
8.3 months for AAP and prednisone alone, respectively; 
11.3 months vs 5.6 months for ENZ and placebo, respec-
tively).7 8 In addition, results from COU-AA-302 showed 
that AAP delayed the time to pain progression (26.7 
months vs 18.4 months with AAP and prednisone, respec-
tively)7 and results from PREVAIL showed that the time to 
deterioration in FACT-P prostate cancer subscale pain-re-
lated score was longer in the ENZ group than in the 
placebo group (8.3 months vs 2.8 months, respectively).9 
Recent findings from a phase II trial (NCT02125357) 
showed more favourable outcomes for quality of life 
(QoL), depression and cognition with AAP versus ENZ in 
chemotherapy-naïve patients with mCRPC.10 11 Data from 
a single-centre study indicated that self-reported phys-
ical and psychological symptoms (assessed by Edmonton 
Symptom Assessment System (ESAS) score) were compa-
rable in men with chemotherapy-naïve mCRPC treated 
with AAP or ENZ in routine clinical practice.12 Data of 
this kind, which compare the effects of AAP versus ENZ 
on PROs in an unselected population in the real-world 
setting, are limited. Cognitive function in particular is an 
understudied PRO in patients with mCRPC.
The phase IV AQUARiUS study was designed to explore 
whether there are differences in PROs (cognitive func-
tion, fatigue, pain and HRQoL) and medical resource use 
between chemotherapy-naïve patients with mCRPC newly 
initiated on AAP or ENZ in the real-world setting. This 
initial 3-month analysis focuses on PRO data only.
MetHods
study design
AQUARiUS (NCT02813408) is an ongoing, two-cohort, 
prospective, observational, non-randomised, multicentre 
phase IV study conducted in Denmark, France and the 
UK. Patients were recruited during routine clinical prac-
tice by office-based or hospital-based urology and/or 
oncology specialists at the point at which treatment with 
either AAP or ENZ was initiated. The decision to treat 
the patient with either agent preceded study enrolment 
and was per routine clinical practice; the treatment and 
clinical care of patients was not influenced by their partic-
ipation in the study. All patients meeting the study criteria 
who visited the study physician were consecutively invited 
to participate in the study to minimise recruitment bias.
Ahead of site initiation, a national or central inde-
pendent ethics committee or institutional review board 
reviewed/received notification of the study, in all coun-
tries, as required by local regulations.
Patients and sample size
To be eligible to take part in the study, patients had to 
meet the following inclusion criteria: males aged ≥18 
years; histologically or cytologically confirmed diagnosis 
of adenocarcinoma of the prostate; documented meta-
static prostate cancer; documented castration resistance 
with progression of prostate cancer on ADT (surgical or 
chemical); and were to be initiated on AAP or ENZ for 
asymptomatic or mildly symptomatic mCRPC after the 
failure of ADT.
Patients were not eligible if they had received any prior 
chemotherapy/cytotoxic agent to treat their mCRPC, 
had received or were currently receiving AAP or ENZ or 
were receiving an investigational treatment for prostate 
cancer of any kind before or at the time of initiation of 
AAP or ENZ treatment.
Prior to data collection, all patients provided informed 
consent in accordance with local requirements. The study 
was conducted according to the principles set forth in the 
Declaration of Helsinki.
Data would be prospectively collected from approx-
imately 211 patients in total, which is the sample size 
required to detect a difference of ≥0.5 SD between the 
two treatment cohorts, with 85% power at the 5% level 
of significance. The number of patients in each cohort 
would be as equal as possible, and recruitment would be 
closely monitored.
endpoints and data collection
Data were collected on paper questionnaires and then 
entered onto electronic case report forms. Patients were 
asked to provide PRO data on cognition, fatigue, pain and 
HRQoL via completion of the following questionnaires: 
the Functional Assessment of Cancer Therapy-Cognitive 
Function (FACT-Cog),13 which comprises four subscales 
(symptoms of perceived cognitive impairments, perceived 
cognitive abilities, comments from others and impact of 
perceived cognitive impairment on QoL); Brief Fatigue 
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Inventory-Short Form (BFI-SF),14 which comprises three 
severity items and six fatigue interference items (disrup-
tion to general activity, mood, walking ability, normal work, 
relations with others and enjoyment of life); Brief Pain 
Inventory-Short Form (BPI-SF),15 comprising four pain 
severity items, seven pain interference items and a ques-
tion regarding percentage of pain relief from analgesics; 
and the European Organization for Research and Treat-
ment of Cancer Quality of Life Questionnaire (EORTC 
QLQ-C30),16 comprising five functional scales (physical, 
role, cognition, emotional and social), three symptom 
scales (fatigue, pain and nausea and vomiting), a global 
health and QoL scale and several single-item symptom 
measures.
Medical records were used to capture data on prostate 
cancer diagnosis and history, baseline patient demographics 
and clinical characteristics and current treatment regimens. 
Collection of PRO data began before administration of AAP 
or ENZ (defined as the baseline visit) and would continue 
until termination of treatment or for approximately 12 
months, whichever occurs first. During the observation 
period, PRO data were collected during a patient’s routine 
visits to the clinic. Study completion was defined as the date 
of last data collection of the last patient in the study (online 
supplementary figure 1 and online supplementary table 1).
data analysis
This current analysis focuses on PROs and was based on 
enrolment of 50% (n=105) of the planned 211 patients 
with 3-month follow-up (cut-off date: 16 February 2017). 
PRO data were analysed at monthly intervals, defined as 28, 
56 or 84 days, ±14 days, following initiation of AAP or ENZ 
treatment.
Two types of analysis were performed to compare the 
treatment groups: (1) the mean change from baseline in 
PRO score, a continuous endpoint, which was analysed 
using multivariate repeated measures linear models, and 
(2) the percentage of patients who showed clinically mean-
ingful worsening versus improvements/no change in PROs, 
a binary endpoint, which was analysed using multivariate 
repeated measures logistic models. A clinically meaningful 
change in status was defined as a difference from baseline 
greater than the minimal important difference (0.5 times 
the SD of the baseline PRO of all patients). If results could 
not be obtained from the multivariate repeated measures 
logistic models due to convergence issues, multivariate 
logistic models fitted for each time period separately were 
used instead.
Both analyses were adjusted for the baseline PRO value 
and for baseline characteristics associated with their corre-
sponding PRO scale. Baseline characteristics considered as 
covariates in the multivariate models included age, Gleason 
score at initial diagnosis, Eastern Cooperative Oncology 
Group performance status, visceral metastases, use of anal-
gesics, use of sedatives, alkaline phosphatase, haemoglobin, 
prostate-specific antigen and number of comorbidities 
(lactate dehydrogenase was excluded due to the number 
of missing values).
The primary analysis is an intention-to-treat analysis; all 
patients were included regardless of whether they switched 
treatment during follow-up. Per-protocol and censoring 
analyses were conducted as sensitivity analyses. In the 
per-protocol analysis, patients who switched were excluded; 
in the censoring analysis, patients were censored at the time 
of switch. The results presented hereafter were based on 
the intent-to-treat population.
Results
A total of 113 patients were examined for eligibility in the 
study; however, eight of these patients did not meet the 
inclusion/exclusion criteria. Therefore, 105 patients were 
included in this initial analysis—46 patients were treated 
with AAP (four of whom received dexamethasone instead 
of prednisone) and 59 were treated with ENZ. Baseline 
characteristics were reasonably well balanced between 
the two treatment cohorts, and no statistically significant 
differences were observed (table 1). As indicated in online 
supplementary table 2, completion of PRO questionnaires 
decreased over the 3-month period in the same range in 
both treatment cohorts.
Patients who switched or discontinued treatment
Within the first 3 months, seven patients (two from the AAP 
group and five from the ENZ group) switched from one 
treatment to the other and four patients (two from the AAP 
group and two from the ENZ group) discontinued treat-
ment. Reasons for discontinuation or switching of treat-
ment are shown in online supplementary table 3.
Analysis 1: mean change from baseline in PRo score
Figure 1 shows the mean difference between treatment 
groups in the mean change from baseline for each scale 
evaluated. As shown, all significant differences observed 
between the two treatment groups favoured AAP over ENZ. 
Figure 2 shows the mean change from baseline at months 1, 
2 and 3 for scales for which a significant difference between 
treatment groups was seen for at least two consecutive time-
points.
Functional Assessment of Cancer Therapy-Cognitive 
Function (FACT-Cog)
Significant differences favouring AAP over ENZ were 
consistent across all three time-points for perceived cogni-
tive impairments (4.67, 95% CI 1.20 to 8.13, p=0.009; 6.60, 
95% CI 2.73 to 10.48, p=0.001; and 6.64, 95% CI 0.84 to 
12.43, p=0.025 at months 1, 2 and 3, respectively) (figure 1 
and 2). Significant differences favouring AAP over ENZ 
were also seen for scale ‘impact on QoL’ at month 1 and 
scale ‘comments from others’ at month 3 (figure 1).
Brief Fatigue Inventory-Short Form (BFI-SF)
At months 2 and 3, significant differences in favour of 
AAP versus ENZ were seen for usual level of fatigue (–1.17, 
95% CI –2.13 to –0.22, p=0.017; and –1.41, 95% CI –2.74 to 
–0.08, p=0.038 at months 2 and 3, respectively) (figure 1 
and 2) and for fatigue interference (–0.99, 95% CI –1.83 to 
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–0.15, p=0.021; and –1.20, 95% CI –2.31 to –0.08, p=0.036 at 
months 2 and 3, respectively) (figure 1 and 2). Significant 
differences favouring AAP over ENZ were also observed at 
month 3 for ‘your fatigue right now’ (–1.41, 95% CI –2.55 
to –0.26, p=0.017) and ‘your worst level of fatigue’ (–1.63, 
95% CI –2.98 to –0.28, p=0.019) (figure 1).
Brief Pain Inventory-Short Form (BPI-SF)
No significant differences between treatment groups were 
observed for any of the pain PRO scales at any time-point 
(figure 1).
European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire-C30 (EORTC QLQ-C30) 
Significant differences favouring AAP over ENZ were 
seen consistently across all time-points for cognitive func-
tioning (6.10, 95% CI 0.92 to 11.28, p=0.021; 9.75, 95% CI 
3.06 to 16.44, p=0.005; and 11.82, 95% CI 0.84 to 22.79, 
p=0.035 at months, 1, 2 and 3, respectively) (figure 1 and 
2). Significant differences favoured AAP over ENZ for the 
fatigue aspect of the questionnaire at month 1 (–9.85, 
95% CI –18.07 to –1.63; p=0.019) and month 3 (–16.20, 
95% CI –28.25 to –4.15, p=0.009) and for the pain aspect 
of the questionnaire at month 3 (–13.59, 95% CI –24.68 
to –2.50, p=0.017) (figure 1). Significant differences also 
favoured AAP over ENZ for emotional functioning and 
appetite loss at months 1 and 3, for role functioning 
at month 1 and for physical functioning at month 3 
(figure 1).
Analysis 2: clinically meaningful change in PRo score
The ORs for patients who showed clinically mean-
ingful worsening versus improvement or no change 
for each PRO scale are presented in figure 3.
Table 1 Baseline characteristics of AAP-treated and ENZ-treated patients
AAP (n=46) ENZ (n=59) P values
Age, years, median (range) n=46
73 (53–90)
n=59
76 (60–92)
0.083
LDH at baseline, IU/L, median (range) n=21
226.00 (130–1207)
n=20
229.50 (170–837)
0.755
ALP at baseline, IU/L, median (range) n=37
94.00 (34–2435)
n=46
91.00 (47–4344)
0.781
PSA at baseline, ng/mL, median (range) n=46
15.56 (1.1–588)
n=59
36.00 (1.3–450)
0.605
Gleason score at initial diagnosis, n (%) 0.944
  ≤7 24 (52.2) 29 (49.2)
  ≥8 18 (39.1) 25 (42.4)
  Missing 4 (8.7) 5 (8.5)
ECOG performance score, n (%) 0.627
  0/1 41 (89.1) 49 (83.1)
  ≥2 4 (8.7) 7 (11.9)
  Missing 1 (2.2) 3 (5.1)
Any visceral metastases, n (%) 0.646
  No 40 (87.0) 53 (89.8)
  Yes 6 (13.0) 6 (10.2)
Anaemia, n (%) 0.810
  Grade ≤2 39 (84.8) 51 (86.4)
  Grade ≥3 0 (0.0) 0 (0.0)
  Missing 7 (15.2) 8 (13.6)
Opioid use at baseline, n (%) 0.694
  No 36 (78.3) 48 (81.4)
  Yes 10 (21.7) 11 (18.6)
Sedative use at baseline, n (%) 0.281
  No 39 (84.8) 54 (91.5)
  Yes 7 (15.2) 5 (8.5)
AAP, abiraterone acetate plus prednisone; ALP, alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group.; ENZ, enzalutamide; 
LDH, lactate dehydrogenase; PSA, prostate-specific antigen.
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Functional Assessment of Cancer Therapy-Cognitive 
Function (FACT-Cog)
Patients treated with ENZ had a significantly higher 
risk of experiencing clinically meaningful worsening 
versus improvement or no change in perceived cognitive 
impairments compared with those treated with AAP at 
months 1, 2 and 3, with ORs for AAP versus ENZ of 0.13, 
95% CI 0.03 to 0.54, p=0.005; 0.06, 95% CI 0.01 to 0.27, 
p<0.001 and 0.14, 95% CI 0.03 to 0.75, p=0.022 for months 
1, 2 and 3, respectively (figure 3 and 4). A significant 
Signicant in favour of AAP Trend in favour of AAP Signi cant in favour of ENZ Trend in favour of ENZ
PRO scale (min–max range) Month 1 Month 2 Month 3
FACT-Cog Difference (95% CI)*
p Value
Difference (95% CI)*
p Value
Difference (95% CI)*
p Value
1. Perceived cognitive impairments (0–72)
4.67 (1.20–8.13)
0.009
6.60 (2.73–10.48)
0.001 
6.64 (0.84–12.43)
0.025 
2. Comments from others (0–16) 
0.66 (–0.08 to 1.39)
0.080 
0.76 (–0.05 to 1.57)
0.065 
1.53 (0.44–2.62)
0.007 
3. Perceived cognitive abilities (0–28)
2.54 (–0.40 to 5.47)
0.090 
3.13 (–0.32 to 6.57)
0.074 
1.40 (–2.35 to 5.14)
0.460 
4. Impact on QoL (0–16)
1.36 (0.00–2.71)
0.050 
0.03 (–1.64 to 1.70)
0.974 
1.37 (–0.58 to 3.32)
0.164 
BFI-SF
Severity
1. Your fatigue right now (0–10)
–0.78 (–1.67 to 0.11)
0.084 
–1.00 (–2.02 to 0.02)
0.055
–1.41 (–2.55 to –0.26)
0.017 
2. Your usual level of fatigue (0–10)
–0.52 (–1.36 to 0.33)
0.230
–1.17 (–2.13 to –0.22)
0.017
–1.41 (–2.74 to –0.08)
0.038 
3. Your worst level of fatigue (0–10)
–0.57 (–1.53 to 0.38)
0.235
–1.09 (–2.22 to 0.05)
0.060
–1.63 (–2.98 to –0.28)
0.019
Fatigue interference
4. Fatigue interference (0–10)
–0.36 (–1.08 to 0.37)
0.330
–0.99 (–1.83 to –0.15)
0.021
–1.20 (–2.31 to –0.08)
0.036
BPI-SF
Severity
1. Pain at its worst (0–10)
0.06 (–0.91 to 1.02)
0.910 
–0.03 (–1.18 to 1.11)
0.952
–0.59 (–1.84 to 0.66)
0.353 
2. Pain at its least (0–10)
–0.28 (–1.02 to 0.46)
0.461 
–0.18 (–1.07 to 0.71)
0.688
–0.46 (–1.36 to 0.44)
0.312
3. Pain on the average (0–10)
0.10 (–0.57 to 0.76)
0.775 
–0.23 (–1.09 to 0.63)
0.602 
–0.59 (–1.61 to 0.42)
0.245 
4. Pain right now (0–10)
–0.30 (–1.07 to 0.47)
0.443
–0.05 (–0.98 to 0.88)
0.912
–0.20 (–1.16 to 0.75)
0.675
Pain interference
5. Pain interference (0–10)
–0.14 (–0.86 to 0.57)
0.689 
–0.36 (–1.18 to 0.47)
0.387
–0.71 (–1.89 to 0.47)
0.231 
QLQ-C30
Functional scales
1. Physical functioning (0–100) 
0.60 (–5.05 to 6.24)
0.834 
–0.09 (–6.91 to 6.73)
0.980
9.38 (1.08 to 17.68)
0.027 
2. Role functioning (0–100)
10.71 (0.08–21.34)
0.048 
9.03 (–1.60 to 19.67)
0.095
12.40 (–0.09 to 24.88)
0.052
3. Emotional functioning (0–100)
6.02 (0.04–12.00)
0.048 
–0.89 (–8.93 to 7.15)
0.826 
5.55 (0.04–11.06)
0.049
4. Cognitive functioning (0–100)
6.10 (0.92–11.28)
0.021 
9.75 (3.06–16.44)
0.005 
11.82 (0.84–22.79)
0.035 
5. Social functioning (0–100)
5.67 (–3.86 to 15.19)
0.241
4.70 (–4.97 to 14.37)
0.336
11.52 (–1.19 to 24.23)
0.075
Symptom scales
6. Fatigue (0–100)
–9.85 (–18.07 to –1.63)
0.019 
–3.94 (–13.31 to 5.42)
0.406
–16.20 (–28.25 to –4.15)
0.009 
7. Nausea and vomiting (0–100)
–3.97 (–9.68 to 1.74)
0.170 
0.83 (–5.72 to 7.37)
0.802 
–5.33 (–12.44 to 1.77)
0.139 
8. Pain (0–100)
–1.76 (–11.23 to 7.72)
0.714 
–6.43 (–17.39 to 4.53)
0.247 
–13.59 (–24.68 to –2.50)
0.017 
9. Dyspnoea (0–100)
–1.26 (–9.10 to 6.57)
0.749 
–2.81 (–12.41 to 6.79)
0.562
–5.13 (–15.29 to 5.04)
0.318 
10. Insomnia (0–100)
-9.75 (–19.83 to 0.33)
0.058 
1.06 (–8.54 to 10.66)
0.826 
–2.67 (–12.21 to 6.87)
0.578
11.  Appetite loss (0–100)
–11.01 (–19.65 to –2.38)
0.013
–7.47 (–17.08 to 2.14)
0.126
–20.25 (–32.73 to –7.77)
0.002 
12.  Constipation (0–100)
–0.76 (–10.11 to 8.59)
0.872 
0.43 (–10.99 to 11.84)
0.941 
–3.76 (–16.04 to 8.52)
0.543 
13. Diarrhoea (0–100)
–3.30 (–10.84 to 4.24)
0.387 
–4.35 (–12.64 to 3.94)
0.299 
–6.59 (–14.80 to 1.63)
0.114 
14. Financial difculties (0–100)
0.92 (–4.77 to 6.60)
0.749 
–4.53 (–10.86 to 1.81)
0.159 
4.45 (–3.03 to 11.93)
0.239 
Global health status/QoL
15. Global health status/QoL (0–100)
4.17 (–2.77 to 11.11)
0.236
7.73 (–2.29 to 17.74)
0.129
7.05 (–4.41 to 18.51)
0.224 
Figure 1 Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 
3. *Evaluable patients. Interpretation of the PRO scales: for FACT-Cog higher scores are favourable; for EORTC QLQ-C30 
functional scales and global health status/QoL higher scores are favourable, for EORTC QLQ-C30 symptom scales lower 
scores are favourable; for BPI-SF and BFI-SF lower scores are favourable. AAP, abiraterone acetate plus prednisone; BFI-SF, 
Brief Fatigue Inventory-Short Form; BPI-SF, Brief Pain Inventory-Short Form; ENZ, enzalutamide; EORTC QLQ-C30, European 
Organization for Research and Treatment of Cancer Quality of Life questionnaire; FACT-Cog, Functional Assessment of Cancer 
Therapy -Cognitive Function; PRO, patient-reported outcome; QoL, quality of life. 
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difference was also seen for ‘comments from others’ at 
month 2 (OR for AAP vs ENZ was 0.23, 95% CI 0.06 to 0.94, 
p=0.041, based on the multivariate logistic model fitted for 
each time period separately; figure 3).
Brief Fatigue Inventory-Short Form (BFI-SF)
The only significant difference for fatigue was seen at 
month 3, at which point there was a significant difference 
favouring AAP over ENZ for usual level of fatigue (the OR 
for clinically meaningful worsening vs improvement or 
no change for AAP vs ENZ was 0.33, 95% CI 0.11 to 0.97, 
p=0.044; figure 3).
Brief Pain Inventory-Short Form (BPI-SF)
There were no significant differences between treatment 
groups for any of the pain scales at any time-point (figure 3).
European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
Significant differences favouring AAP over ENZ were 
seen for cognitive functioning at month 1 (OR for clin-
ically meaningful worsening vs improvement or no 
change for AAP vs ENZ was 0.09, 95% CI 0.02 to 0.49, 
p=0.006; figure 3). A significant difference favouring AAP 
over ENZ was seen for fatigue at month 1 (OR for AAP 
vs ENZ was 0.24, 95% CI 0.06 to 0.90, p=0.034, based on 
the multivariate logistic model fitted for each time period 
separately; figure 3). Significant differences favouring 
AAP versus ENZ were also seen for emotional functioning 
at month 1, global health status/QoL at month 2, phys-
ical functioning at month 3 and appetite loss at months 1 
and 3 (figure 3).
Figure 2 Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue 
(C) and fatigue interference (D) at months 1, 2 and 3. For FACT-Cog higher scores are favourable; for EORTC QLQ-C30 
functional scales and global health status/QoL higher scores are favourable, for EORTC QLQ-C30 symptom scales lower 
scores are favourable; for BPI-SF and BPI-SF lower scores are favourable AAP, abiraterone acetate plus prednisone; BFI-
SF, Brief Fatigue Inventory-Short Form; BPI-SF, Brief Pain Inventory-Short Form; CI, confidence interval; ENZ, enzalutamide; 
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life questionnaire; FACT-Cog, 
Functional Assessment of Cancer Therapy -Cognitive Function; PRO, patient-reported outcome. 
 o
n
 13 Septem
ber 2018 by guest. Protected by copyright.
http://esm
oopen.bmj.com/
ESM
O
 O
pen: first published as 10.1136/esm
oopen-2018-000397 on 3 August 2018. Downloaded from
 
Open access
7Thiery-Vuillemin A, et al. ESMO Open 2018;3:e000397. doi:10.1136/esmoopen-2018-000397 Thiery-Vuillemin A, et al. ESMO Open 2018;3:e000397. doi:10.1136/esmoopen-2018-000397
Results of the per-protocol analysis and the censoring 
analysis remained consistent with those presented for the 
intent-to treat analysis.
dIsCussIon
Initial results from the AQUARiUS study showed that 
cognitive outcome measures were consistently more 
favourable with AAP versus ENZ over the three time-points 
assessed. Significant differences favouring AAP over ENZ 
in mean change from baseline in perceived cognitive 
impairments, as assessed using the FACT-Cog question-
naire, were observed at months 1, 2 and 3. In addition, 
the risk of clinically meaningful worsening of perceived 
cognitive impairments, again assessed via FACT-Cog, was 
significantly greater with ENZ treatment compared with 
AAP, at each of the three time-points. These findings 
PRO scale Month 1 Month 2 Month 3
FACT-Cog
Odds ratio (95% CI)†
p Value
Odds ratio (95% CI)†
p Value
Odds ratio (95% CI)†
p Value
1. Perceived cognitive impairments 
0.13 (0.03–0.54)
0.005
0.06  (0.01–0.27)
<0.001
0.14 (0.03–0.75)
0.022
2. Comments from others‡
0.31 (0.09–1.07)
0.065 
0.23 (0.06–0.94)
0.041
–
3. Perceived cognitive abilities
0.47 (0.15–1.47)
0.192 
0.40 (0.11–1.45)
0.163
0.53 (0.11–2.45)
0.416
4. Impact on QoL 
0.62 (0.20–1.89)
0.401 
1.33 (0.41–4.27)
0.634
0.49 (0.15–1.60)
0.237
BFI-SF
Severity
1. Your fatigue right now 
0.85 (0.30–2.40)
0.754 
0.80 (0.27–2.37)
0.683
0.38 (0.11–1.29)
0.121
2. Your usual level of fatigue 
0.68 (0.25–1.81)
0.437
0.53 (0.17–1.64)
0.272
0.33 (0.11–0.97)
0.044
3. Your worst level of fatigue
1.11 (0.38–3.26)
0.847
0.90 (0.27–3.03)
0.863
0.57 (0.15–2.11)
0.399
Fatigue interference
4. Fatigue interference 
0.59 (0.18–1.93)
0.384
0.76 (0.27–2.15)
0.611
0.53 (0.17–1.62)
0.265
BPI-SF
Severity
1. Pain at its worst†
3.50 (0.84–14.61)
0.086 
2.82 (0.64–12.47)
0.171
0.94 (0.19–4.69)
0.940
2. Pain at its least 
0.74 (0.26–2.10)
0.569 
0.70 (0.25–1.95)
0.493
0.62 (0.17–2.26)
0.466
3. Pain on the average‡ –
2.59 (0.44–15.33)
0.293
0.96 (0.20–4.76)
0.964
4. Pain right now 
1.25 (0.32–4.79)
0.748
0.87 (0.26–2.91)
0.820
1.34 (0.25–7.14)
0.730
Pain interference
5. Pain interference
0.43 (0.08–2.28)
0.319
0.36 (0.11–1.18)
0.091
0.77 (0.21–2.91)
0.705
QLQ-C30
Functional scales
1. Physical functioning 
0.65 (0.24–1.75)
0.396
2.07  (0.63–6.80)
0.230
0.14 (0.03–0.73)
0.019
2. Role functioning 
0.45 (0.17–1.24)
0.125 
0.84 (0.32–2.18)
0.713
0.45 (0.16–1.27)
0.130
3. Emotional functioning 
0.08 (0.01–0.84)
0.036
1.29 (0.32–5.17)
0.716
0.89 (0.21–3.80)
0.879
4. Cognitive functioning 
0.09 (0.02–0.49)
0.006 
0.22 (0.05–1.06)
0.060
0.45 (0.12–1.75)
0.250
5. Social functioning 
1.80 (0.66–4.93)
0.251
1.09 (0.36–3.28)
0.879
0.84 (0.28–2.48)
0.752
Symptom scales
6. Fatigue 
0.24 (0.06–0.90)
0.034
0.61 (0.18–2.09)
0.433
0.37 (0.05–2.72)
0.329
7. Nausea and vomiting 
1.59 (0.54–4.73)
0.401 
1.92 (0.54–6.83)
0.312
0.59 (0.16–2.19)
0.428
8. Pain 
1.12 (0.41–3.06)
0.832 
0.71 (0.24–2.12)
0.539
0.46 (0.13–1.68)
0.241
9. Dyspnoea 
0.93 (0.30–2.91)
0.900
0.66 (0.21–2.14)
0.492
0.31 (0.05–1.76)
0.186
10. Insomnia
0.50 (0.15–1.64)
0.254
0.57 (0.16–2.00)
0.384
1.19 (0.29–4.92)
0.815
11. Appetite loss 
0.20 (0.04–0.99)
0.049
0.31 (0.07–1.34)
0.117
0.12 (0.02–0.63)
0.012
12. Constipation
0.96 (0.29–3.13)
0.940
1.31 (0.35–4.99)
0.691
0.82 (0.22–3.10)
0.769
13. Diarrhoea 
0.83 (0.20–3.47)
0.793
0.09 (0.01–1.05)
0.054
0.30 (0.03–2.89)
0.299
14. Financial difculties‡
0.78 (0.12–4.92)
0.789
0.28 (0.03–2.61)
0.262
– 
Global health status/QoL
15. Global health status/QoL 
0.47 (0.16–1.42)
0.183
0.25 (0.07–0.91)
0.036
0.47 (0.11–1.95)
0.300 
Signicant in favour of AAP Trend in favour of AAP Signi cant in favour of ENZ Trend in favour of ENZ
Figure 3 Clinically meaningful worsening (versus improvement or no change)* for AAP (n=46) vs ENZ (n=59) for all PRO 
scales evaluated.  *Defined as the difference from baseline ≥ minimal important difference (0.5 × SD of baseline PRO of all 
patients). †Evaluable patients. ‡Results could not be obtained from the multivariate repeated measures logistic models for 
these scenarios due to convergence issues. Instead they are taken from multivariate logistic models fitted for each time period 
separately. (For all scenarios for which both type of models could be fit, results were very much in line.) Empty cells are the 
results of zero counts and therefore modelling is not possible. Interpretation of the PRO scales: for FACT-Cog higher scores 
are favourable; for EORTC QLQ-C30 functional scales and global health status/QoL higher scores are favourable, for EORTC 
QLQ-C30 symptom scales lower scores are favourable; for BPI-SF and BFI-SF lower scores are favourable. 
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were supported by the cognitive functioning aspect of 
the QLQ-C30 questionnaire, which showed a significant 
difference in cognitive functioning at months 1, 2 and 3 
in favour of AAP over ENZ.
There were significant differences between treatment 
groups favouring AAP over ENZ in mean change from 
baseline in usual level of fatigue and fatigue interference, 
as assessed using the BFI-SF at months 2 and 3, and for all 
fatigue scales at month 3. Furthermore, results of the clin-
ically meaningful change from baseline analysis demon-
strated that usual level of fatigue was significantly more 
likely to worsen in those treated with ENZ compared with 
those treated with AAP at month 3. Significant differences 
between treatment groups for mean change in baseline 
were also observed for the fatigue aspect of the EORTC 
QLC-30 questionnaire at months 1 and 3. No significant 
differences were observed for pain outcomes measures, 
as assessed using the BPI-SF, in either of the two analyses 
at any time-point.
Our finding that the effects of AAP and ENZ on PROs 
can be observed during the first 3 months of treatment, 
and in some cases as early as month 1, is not surprising as 
with daily dosing abiraterone and ENZ reach steady state 
by days 9 and 28, respectively6 17 and have previously been 
shown to affect patient symptoms such as pain within a 
similar treatment period (approximately 3 months).9 18
Our study suggests that in order to improve adherence 
to therapy, particular attention is warranted in the clin-
ical management of patients over the first 3 months of 
treatment. In the current analysis of AQUARiUS, seven 
patients from the ENZ cohort switched or discontinued 
treatment (five of which were due to safety reasons) 
compared with four from the AAP cohort (one of which 
was due to safety reasons). Identifying these patients 
early may improve their management and compliance to 
further alternative treatment.
Our findings are consistent with those of other recent 
reports. The effects of AAP and ENZ on PROs have 
been compared directly in a phase II, randomised, cross-
over trial (NCT02125357) designed to assess treatment 
sequence in chemotherapy-naïve patients with mCRPC. 
Findings showed that after 12 weeks of treatment, median 
QoL score (total FACT-P score) improved with AAP, 
whereas there was no change with ENZ; for the physical 
well-being subscale, there was a higher rate of signifi-
cant worsening with ENZ versus AAP.10 More patients 
receiving ENZ experienced worsening of depression 
symptoms per Patient Health Questionnaire-9, compared 
with those taking AAP, and a trend towards worsening in 
cognitive impairment, as assessed with Montreal Cogni-
tive Association testing, was observed with ENZ compared 
with AAP.10 11 Further follow-up analyses are required to 
confirm these findings.
The effects of AAP and ENZ on self-reported symptom 
burden were found to be comparable in a single-centre 
study in 189 men with chemotherapy-naïve mCRPC in 
routine clinical practice.12 Fatigue was considered the 
most distressing symptom in both groups at baseline and 
following treatment. Results were similar for AAP-treated 
and ENZ-treated patients in terms of significant differ-
ences from baseline in ESAS score and in the proportion 
of patients with clinically meaningful symptom improve-
ment or worsening.12 Of note, the ESAS is designed to 
assess pain, activity, nausea, depression, anxiety, drowsi-
ness, appetite, well-being and shortness of breath but 
does not include an evaluation of cognitive function.19
Deterioration of PROs may be experienced soon after 
treatment initiation, as demonstrated in the AQUARiUS 
study, with cognitive deterioration and fatigue progres-
sion occurring within the first 3 months. These effects 
are likely to affect a patient’s QoL significantly but may 
also reduce adherence to medication and therefore result 
Figure 4 Proportion of patients showing clinically meaningful worsening, improvement or no change in perceived cognitive 
impairments for AAP versus ENZ at months 1, 2 and 3. *Worsening versus improvement or no change. AAP, abiraterone 
acetate plus prednisone; CI, confidence interval; ENZ, enzalutamide.
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in suboptimal clinical responses. Several studies suggest 
that PROs significantly impact clinical outcomes, such as 
disease progression and mortality. For example, an anal-
ysis of data from COU-AA-302 showed that worsening 
PROs (pain, physical well-being, functional well-being 
and prostate cancer-specific signs and symptoms) were 
associated with a greater risk of radiographic progression 
compared with stable or improved PRO scores.20 In an 
analysis of data from the PREVAIL and AFFIRM studies—
which were conducted in patients treated with ENZ prior 
to or post chemotherapy, respectively—overall survival 
was associated with multiple HRQoL measures, including 
FACT-P total score.21 Furthermore, an analysis of three 
phase III studies in men with CRPC found a significant 
association between pain interference scores and risk of 
death.22 These findings highlight the need to consider 
PROs when managing mCRPC in order to achieve optimal 
treatment outcomes and ensure that the balance between 
benefit and harm are acceptable to patients.23 Results 
from a discrete choice experiment showed that men with 
mCRPC take a wide range of factors into consideration 
when making decisions regarding their treatment.24 
They had a strong preference for treatments that could 
offer better control of bone pain and also valued those 
that could delay the need for chemotherapy, as well as 
those that had fewer adverse events such as cognition and 
memory loss and extreme tiredness.24 Treatment should 
be tailored to patients based on their individual needs; 
for example, a treatment associated with fatigue may be 
something to avoid in those who are still employed or 
partake in active exercise.
Phase III trials have demonstrated that AAP and ENZ 
lead to delayed radiographic progression and increased 
survival compared with prednisone or placebo, respec-
tively.7 8 Although extending life expectancy is considered 
the gold standard for treatment, HRQoL is increasingly 
being considered an important endpoint.25 AAP-treated 
and ENZ-treated patients showed more favourable PROs 
than controls in clinical trials7 8; however, the effect of 
AAP compared with ENZ in terms of PROs, and cognition 
in particular, has not been extensively studied. Further-
more, data comparing the effects of these agents on PROS 
in the real-world setting are limited. Having dedicated 
PRO data from a study such as AQUARiUS, with ‘real life’ 
patients, may aid clinicians to treat patients more effec-
tively. PRO data from AQUARiUS may be complemented 
by those from the Cog-Pro study (NCT02907372), which 
is designed to prospectively assess the effect of ENZ and 
AAP on cognitive function in patients with mCRPC and 
evaluate the effect of cognitive impairments on QoL and 
adherence.26
One of the major strengths of the AQUARiUS study 
is its real-world setting. Patients are not limited by strict 
inclusion and exclusion criteria or treatment regimen, 
as in a clinical trial; instead, an unselected population is 
treated as per routine clinical practice. Other strengths of 
the study include the comprehensive assessment of PROs, 
which capture patient perspectives on a range of aspects 
likely to significantly affect activities of daily living, and 
the monthly collection of PRO data, starting from within 
the first month after treatment initiation, allowing very 
early signals to be identified. A further strength is the use 
of primary rather than secondary data for all baseline 
characteristics.
An important limitation of the AQUARiUS study is 
the lack of randomisation. To help address this issue, a 
multivariate modelling approach correcting for all rele-
vant baseline characteristics was used to minimise bias. 
Limitations related to this initial analysis include the 
small sample size (n=105) and the fact that not all PRO 
scales were completed by all patients at each time-point. 
As expected, the proportion of patients who completed 
PROs decreased over time due to discontinuations and 
because PRO data were collected at routine clinical visits 
that did not take place at strict monthly intervals for all 
patients. Therefore, more mature data from a larger 
population of patients, which will be available for future 
analyses of AQUARiUS, are needed to confirm these early 
findings.
In conclusion, initial results from AQUARiUS indicate 
significant benefits with AAP versus ENZ for cognitive 
outcome measures, with differences observed during the 
first month after treatment initiation and persisting over 3 
months. AAP also had a favourable effect on fatigue, with 
differences showing at month 3 across all fatigue scales 
evaluated. No significant differences between treatment 
groups were observed for pain outcomes, as assessed with 
the BPI-SF, at any time-point. These findings are based on 
initial data and await confirmation from future analyses, 
which will include a greater number of patients with a 
longer follow-up period. This study provides novel and 
valuable data regarding PRO outcomes with AAP versus 
ENZ in the real-world setting. Such data are crucial in 
informing clinical decision making, helping to ensure 
that patients with mCRPC receive the most appropriate 
treatment based on their own experiences.
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